Researchers are focused on maintaining an excellent cure rate in diffuse large B-cell lymphoma (DLBCL) and minimizing some of the treatment individuals receive – reduce the number of cycles of chemotherapy or avoid radiation, and looking at new drugs to improve the cure rate for others with DLBCL.

Join us as we chat with Dr. John Kuruvilla, working as a hematologist-oncologist for 20 years (currently at the Princess Margaret Cancer Centre in Toronto) including as a researcher in DLBCL, which is the largest form on non-Hodgkin lymphoma.

Learn more about DLBCL at: 

https://www.bloodcancers.ca/diffuse-large-b-cell-lymphoma-dlbcl